Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2019; 14(04): 1218-1221
DOI: 10.4103/ajns.AJNS_158_19
Case Report

The usefulness of straight chemotherapy for dermal exposed anaplastic lymphoma kinase fusion-positive anaplastic large-cell lymphoma with intracranial invasion

Hiroyuki Abe
0   Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama
,
Taishi Nakamura
0   Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama
,
Masahiro Yoshitomi
1   Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama
,
Makiko Enaka
2   Department of Pathology, Yokohama City University Hospital, Yokohama
,
Kensuke Tateishi
0   Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama
,
Norio Shiba
1   Department of Pediatrics, Graduate School of Medicine, Yokohama City University, Yokohama
,
Shoji Yamanaka
2   Department of Pathology, Yokohama City University Hospital, Yokohama
,
Tetsuya Yamamoto
0   Department of Neurosurgery, Graduate School of Medicine, Yokohama City University, Yokohama
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Anaplastic large-cell lymphoma (ALCL) is characterized as extranodal lymphoma and usually chemosensitive disease with overall survival rate of 70%–90%. Prognosis is roughly distinguished by the existence of anaplastic lymphoma kinase (ALK) fusion in tumor cells with higher frequencies observed in the pediatric population, and the outcome of ALK fusion-positive ALCL is relatively good when appropriate treatment is completed. Here, we report a case of dermal-exposed ALK fusion-positive ALCL with intracranial invasion. The patient received straight chemotherapy (ALCL99 protocol) without any plastic or resection surgery. The dermal dehiscence was rapidly healed with controllable local infection, and the tumor was regressed without relapse. Therefore, straight chemotherapy has clinical relevance and is a useful treatment strategy for ALK fusion-positive ALCL with dermal dehiscence.

Key-words:

Anaplastic large cell lymphoma - anaplastic lymphoma kinase fusion intracranial - skin exposure

Financial support and sponsorship

This study was partially funded by KAKENHI Grants-in-Aid for Scientific Research, 18K16565 (T.N.).




Publication History

Article published online:
09 September 2022

© 2019. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: Report from the international peripheral T-cell lymphoma project. Blood 2008;111:5496-504.
  • 2 Vose J, Armitage J, Weisenburger D. International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: Pathology findings and clinical outcomes. J Clin Oncol 2008;26:4124-30.
  • 3 Falini B, Bigerna B, Fizzotti M, Pulford K, Pileri SA, Delsol G, et al. ALK expression defines a distinct group of T/null lymphomas (“ALK lymphomas”) with a wide morphological spectrum. Am J Pathol 1998;153:875-86.
  • 4 Weisenburger DD, Anderson JR, Diebold J, Gascoyne RD, MacLennan KA, Müller-Hermelink HK, et al. Systemic anaplastic large-cell lymphoma: Results from the non-Hodgkin's lymphoma classification project. Am J Hematol 2001;67:172-8.
  • 5 Shehan JM, Kalaaji AN, Markovic SN, Ahmed I. Management of multifocal primary cutaneous CD30 anaplastic large cell lymphoma. J Am Acad Dermatol 2004;51:103-10.
  • 6 Rodig SJ, Mino-Kenudson M, Dacic S, Yeap BY, Shaw A, Barletta JA, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the Western population. Clin Cancer Res 2009;15:5216-23.
  • 7 Brugières L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL group. J Clin Oncol 2009;27:897-903.
  • 8 Stein H, Mason DY, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the HODGKIN'S disease associated antigen ki-1 in reactive and neoplastic lymphoid tissue: Evidence that reed-sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985;66:848-58.
  • 9 Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: Results of the randomized ALCL99-vinblastine trial. J Clin Oncol 2010;28:3987-93.
  • 10 Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
  • 11 Mossé YP, Lim MS, Voss SD, Wilner K, Ruffner K, Laliberte J, et al. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: A children's oncology group phase 1 consortium study. Lancet Oncol 2013;14:472-80.